

IL-13 Protein, Human (CHO)

Cat. No.:	HY-P7033
Synonyms:	rHuIL-13; NC30
Species:	Human
Source:	CHO
Accession:	P35225 (S33-N146)
Gene ID:	3596
Molecular Weight:	10-25 kDa, under reducing conditions & 25-45 kDa, under non-reducing conditions

PROPERTIES

AA Sequence	<p>S P G P V P P S T A L R E L I E E L V N I T Q N Q K A P L C N G S M V W S I N L</p> <p>T A G M Y C A A L E S L I N V S G C S A I E K T Q R M L S G F C P H K V S A G Q</p> <p>F S S L H V R D T K I E V A Q F V K D L L L H L K K L F R E G R F N</p>
Biological Activity	Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED ₅₀ for this effect is ≤24.04 ng/mL, corresponding to a specific activity is ≥4.20×10 ⁴ U/mg.
Appearance	Lyophilized powder.
Formulation	Lyophilized after extensive dialysis against PBS or 20 mM PB, 150 mM NaCl, pH 7.4.
Endotoxin Level	<1 EU/μg, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	<p>Interleukin-13 is a cytokine which is secreted by activated T lymphocytes and primarily impacts monocytes, macrophages, and B cells. The circular dichroism spectrum confirms that interleukin-13 belongs to the alpha-helical family of cytokines. Interleukin-13 affects the morphology, growth, and surface antigen expression and phenotype of monocytes and elicits B cell proliferation, Ig class switching to IgE synthesis, and enhanced production of IgG4 and IgM. In human macrophages and monocytes, hIL-13 has been shown to inhibit HIV replication. Human IL-13 also inhibits proinflammatory cyto-kines induced by LPS exposure, indicating potential therapeutic applications as an anti-inflammatory agent^[1].</p>
------------	--

REFERENCES

[1]. Cannon-Carlson S, et al. Expression, purification, and characterization of recombinant human interleukin-13 from NS-O cells. Protein Expr Purif. 1998 Mar;12(2):239-48.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA